ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2017 American Transplant Congress

April 29-May 3, 2017 in Chicago, IL

View by Title View Sessions
View by Date
Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z
  • A Brief Frailty Assessment and Outcomes Among Candidates for Liver Transplantation.

    M. Serper, K. Dwinnells, T. Bittermann, K. Olthoff.

  • A Clinically Relevant Protocol for Vascularized Composite Allotransplantation Using a Single Dose of AMD3100 for Stem Cell Mobilization.

    B. Swearingen,1,2 S. Graves,2,3 R. Storb,2,3 D. Mathes.1,2

  • A Combination of Anti-CD40L-Ab, Rapamycin, and Donor Apoptotic Cells Prolongs Allogeneic Pancreatic Islet Survival in Sensitized Mice by Regulating Memory Responses.

    A. Dangi,1 H.-K. Kang,1 X. Zhang,2,3 X. Luo.1,2,3

  • A Comparative Study of Patient and Graft Qualities Between Abo-Compatible and -Incompatible Recipients More Than Ten Years After Kidney Transplantation.

    H. Ishida, T. Shimizu, M. Okumi, K. Unagami, K. Omoto, K. Tanabe.

  • A Comparison of Desensitization Protocols: Rituximab with/without Plasmapheresis in ABO-Incompatible Living Donor Liver Transplantation.

    E. Lee, S. Kim, S. Lee, S.-J. Park.

  • A Comparison of Medical Costs Among ABO-Compatible, -Incompatible, and -Minor Mismatched Living Kidney Transplantation: A Single-Center Study.

    D. Fujimori, M. Okumi, K. Ungami, H. Ishida, K. Tanabe.

  • A Composite Score Associated with Spontaneous Operational Tolerance in Kidney Transplant Recipients.

    R. Danger,1 M. Chesneau,1 C. Paul,1 P. Guérif,1 M. Durand,1 K. Newell,2 S. Kanaparthi,3 L. Turka,4 J.-P. Soulillou,1 R. Houlgatte,5 M. Giral,1,6 G. Ramstein,7 S. Brouard.1,6

  • A Cost Comparison for Telehealth Utilization in the Kidney Transplant Waitlist Evaluation Process at a VA Center.

    R. Forbes, D. Rybacki, T. Johnson, D. Shaffer, D. Hale.

  • A Critical Analysis of Equations for MPA Exposure in Patients Under EC-MPS and Tacrolimus.

    E. David-Neto, A. Triboni, F. Ramos, F. Agena, P. Romano, G. Freitas.

  • A Decade of Paediatric Kidney Transplantation in Children Weighing <20kg.

    P. Chandak,1 J. Stojanovic,2 F. Jamshaid,1 N. Mamode,1 F. Calder,1 J. Olsburgh,1 C. Callaghan,1 M. Drage,1 G. Koffman,1 S. Marks,3 N. Kessaris.1

  • A Dedicated Young Adult Service with a Youth Worker Increases Engagement of Teenagers and Young Adults with Kidney Transplantation and Impacts Favourably on Clinical Outcomes.

    D. Cross, P. Harden.

  • A Donor BMI Greater Than 30 Is Not a Contraindication for Live Liver Donation.

    N. Goldaracena, A. Doyle, D. Al-Adra, G. Sapisochin, M. Cattral, P. Greig, L. Lilly, I. McGilvray, A. Ghanekar, D. Grant, N. Selzner, M. Selzner.

  • A Humanized Anti-CD47 Monoclonal Antibody Therapy Alleviates Ischemia-Reperfusion Injury of Porcine Renal Allografts Donated After Cardiac Death.

    M. Xu,1 B. Banan,1 X. Wang,1 D. Chirumbole,1 B. Rabe,1 S. Garcia-Aroz,1 D. Nayak,1 Z. Zhang,1 J. Jia,1 G. Upadhya,1 J. Gaut,2 P. Manning,3 Y. Lin,1 W. Chapman.1

  • A Kidney Paired Donation Standard Acquisition Charge.

    M. Rees,1,2 L. Reece,2 S. Rees,2 B. Crandall,3 A. Leichtman.4

  • A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence.

    W.-C. Lee, Y.-C. Wang, C.-H. Cheng, T.-H. Wu, C.-F. Lee, T.-J. Wu, H.-S. Chou, K.-M. Chan.

  • A Lower Mean Exposure to Tacrolimus, Not Intra-Patient Variability Is Associated with Chronic Active Antibody Mediated Rejection.

    K. Sablik,1 M. Clahsen–van Groningen,2 T. Van Gelder,1 M. Betjes.1

  • A Markov Model for Transplant & Renal Outcomes After Liver & Simultaneous Liver-Kidney Transplants.

    X. Cheng,1 W. Kim,2 J. Tan,1 J. Goldhaber-Fiebert.3

  • A Molecular Approach to Chronic Rejection: Antibody or T-Cell Mediated?

    L. Kamal, P. O Broin, M. Lubetzky, Y. Bao, E. Akalin.

  • A Molecular Signature Characterized by Dominance of Negative Regulation over Cytotoxic Effectors in Tolerant Kidney Allograft Recipients.

    J. Lee,1 J. Leventhal,2 C. Li,1 A. Katapodis,3 S. Ildstad,4 M. Suthanthiran.1

  • A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.

    N. Kapila,1 B. Zervos,2 B. Ismail,1 C. Lindenmeyer,3 V. Sanghi,3 K. Menon,3 G. Schnickel,2 J. Rivas,2 D. Reino,2 A. Tzakis.2

  • A Multicenter, Prospective and Randomized Trial Comparing Pancreas versus Islet Transplantation: Should We Do It Now?

    D. Cantarovich, P.-Y. Benhamou.

  • A Multidimensional Prognostic Score and Nomogram to Predict Kidney Transplant Survival: The Integrative Box (iBox) System.

    A. Loupy,1 O. Aubert,1 B. Orandi,2 A. Jackson,2 M. Naesens,3 N. Kamar,1 O. Thaunat,1 E. Morelon,1 M. Delahousse,1 D. Viglietti,1 D. Glotz,1 C. Legendre,1 X. Jouven,1 R. Montgomery,2 M. Stegall,4 D. Segev,2 C. Lefaucheur.1

  • A Multistate Modeling Analysis of Time-Varying CPRA States and Its Impact on Kidney Transplant: A Focus on KAS Implementation.

    S. Kulkarni,1 I. Hall,2 R. Formica,1 D. Stewart,3 E. Greene,4 Y. Deng.4

  • A Mutation of the Erythropoietin Receptor Correlates with Improved Function of Deceased-Donor Renal Transplants.

    M. Fischereder,1 S. Friedrich,1 U. Klingmüller,2 T. Kauke,3 T. Breidenbach,4 D. Boesebeck,5 E. Angelika,5 C. Cohen,1 B. Banas,6 M. Guba,7 M. Stangl,8 B. Krämer,9 C. Hugo,10 K. Lopau,11 M. Stadtler,12 T. Mone.12

  • A Nationwide Global Strategy for Kidney Transplantation with Controlled Cardiac Death Donor (cDCD) Has Improved Global Results. Spanish Multicentre SENTRA-GEODAS Group.

    J. Portoles,1,2 M. Perez-Saez,2,3 D. Janeiro,1,2 E. Melilli,2 N. Maruri Kareaga,2 E. de Souza,2 F. Llamas,2 J. Espi,2 P. Martin Moreno,2 D. Navarro,2 A. Sancho-Calabuig,2 M. Rodriguez-Ferrero,2 D. Hernandez,2 J. Pascual.2,3

  • A New and Potent Distal Enhancer of the IL2 Gene.

    R. Thomas,1 P. Mehra,1 M. Johnson,2 S. Grant,2 A. Wells.1

  • A New Methodology for Measuring and Monitoring Equity in Access to Deceased Donor Kidney Transplants.

    D. Stewart, A. Wilk, W. Cherikh, A. Harper, R. Urban, D. Klassen, E. Edwards.

  • A New Strategy for Loco-Regional Therapy of Hepatocellular Carcinoma: Stereotactic Body Radiotherapy as a Bridge to Liver Transplantation.

    T. Uemura,1 A. Kirichenko,2 M. Bunker,3 M. Vincent,1 L. Machado,1 A. Singhal,1 N. Thai.1

  • A Non-Invasive Urinary Common Rejection Module (uCRM) Gene Expression Score Quantifies and Differentiates Kidney Transplant Injury.

    T. Sigdel,1 J. Yang,1 O. Bestard,2 S.-C. Hsieh,1 S. Roedder,2 I. Damm,1 J. Liberto,1 S. Nandoe,1 M. Sarwal.1

  • A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.

    J. Driscoll,1 S. Tremblay,2 S. Knechtle,3 E. Woodle.2

  • A Novel Belatacept Regimen to Optimize Efficacy and Safety.

    D. Wojciechowski,1 S. Chandran,2 M. Sarwal,2 J. Yang,2 F. Vincenti.2

  • A Novel Computational HLA Matching Algorithm for Improving Donor-Recipient Histocompatibility and Graft Outcomes After Kidney Transplantation.

    V. Kosmoliaptsis,1 D. Mallon,1 S. Fuggle,2 R. Johnson,2 C. Watson,1 J. Bradley,1 C. Taylor.1

  • A Novel Endpoint for Evaluating the Effect of Everolimus with Reduced Calcineurin Inhibitor on Long-Term Kidney Graft Outcome: The TRANSFORM Study Protocol.

    T. Srinivas,1 C. Legendre,1 F. Oppenheimer,1 H. Tedesco-Silva,1 W.-L. Luo,2 P. Bernhardt,2 C. Sommerer,1 S. Chadban,1 F. Vincenti,1 J. Pascual.1

  • A Novel Equation, GRAIL (GfR Assessment in Liver Disease) Correctly Classifies Patients with Reduced GFR and Predicts Development of ESRD.

    S. Asrani,1 L. Jennings,1 M. Nadim,2 J. Levitsky,3 J. Trotter,1 G. Klintmalm.1

  • A Novel KPD Mechanism to Increase Transplants When Some Candidates Have Multiple Willing Donors.

    T. Sandholm,1 G. Farina,1 J. Dickerson,2 R. Leishman,3 D. Stewart,3 R. Formica,4 C. Thiessen,4 S. Kulkarni.4

  • A Novel Method for Detecting and Monitoring Chimerism in Patients with Graft versus Host Disease After Liver Transplantation.

    B. Peng, H. Liu, K. Cheng, Y. Zhao, X. She, Y. Niu, Q. Zhuang, Y. Ming.

  • A Novel Method for iNKT Cell-Mediated Ex Vivo Treg Expansion Applied to Induce Human Transplant Tolerance.

    H. Katsumata,1,2 M. Ikemiyagi,1 S. Miyairi,1 R. Ishii,1 T. Kanzawa,1 H. Fukuda,1 T. Hirai,1 M. Okumi,1 Y. Ishii,3 K. Tanabe.1

  • A Novel Microsurgical Penis Transplant Model to Study Distinct Immunologic Features of Urogenital Tissues.

    G. Furtmüller, S. Fidder, B. Simons, B. Oh, B. Kern, D. Lough, M. Chicco, C. Brayton, W. Lee, D. Cooney, R. Redett, G. Brandacher.

  • A Novel MyD88 Inhibitor Attenuates Allograft Rejection in Heterotopic Tracheal Transplantation in Mice.

    M. Yang, X. Zhang, G. Chen, Z.-C. Ding, Y. Miao, Y. Yang, P. Zhou.

  • A Novel Role for MyD88 Signaling Downstream from Toll-Like Receptors in B Cells Responding to Blood Group Antigens.

    H. Sakai, Y. Tanaka, H. Ohdan.

  • A Novel Technique to Increase Donor Utilization: Our Experience Using High-Dose Tissue Plasminogen Activator Flush in Donation-After-Cardiac-Death Donors for Liver Transplantation.

    J. Graham, K. Lorenzen, S. Bellemare, M. Kinkhabwala, J. Rocca.

  • A Novel, Dose-Adjusted Tacrolimus Trough Concentration (TTC) Model for Prediction and Variance Estimation.

    J. Kim,1 S. Wilson,1 N. Undre,2 S. Fei,1 R. Kristy,1 J. Schwartz.1

  • A Phase Ib, Open Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End-Stage Renal Disease.

    B. Abu Jawdeh,1 E. Woodle,1 A. Leino,1 T. Dorst,1 M. Abdallah,1 A. Govil,1 D. Byczkowski,2 H. Misra,2 A. Abuchowski,2 R. Alloway.1

  • A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.

    G. Banham,1,2 S. Flint,3 N. Torpey,2 P. Lyons,1 D. Shanahan,3 A. Gibson,3 A.-M. O'Sullivan,2 R. Jones,1,2,3 L. Devey,3 A. Richards,3 L. Erwig,3 C. Savage,3 K. Smith,1,2 R. Henderson,3 M. Clatworthy.1,2

  • A Pilot Test of the "Individualized Self-Management Training in Adolescent/Young Adult Recipients of Transplantation (iSTART)" Program.

    E. Fredericks, S. Eder, D. Egleston, W. Newhouse, D. O'Reilly, G. Freed, J. Magee, K. Resnicow.

  • A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.

    S. Min, T. Daljevic, M. Lafreniere-Roula, C. Manlhiot, N. Nalli, H. Grasemann, S. Schwartz, B. Kamath, V. Ng, R. Parekh, S. Mital.

  • A Possible Unintended Consequence of the Kidney Allocation System: The Effect of Duration of Dialysis on Mental Health Outcomes.

    S. Radomski,1,2 I. Feurer,2 R. Forbes,2 B. Concepcion,2 H. Schaefer.2

  • A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium.

    V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.

  • A Promising MyD88 Inhibitor TJ-M2010-2 Protects Heart from Myocardial Ischemia Reperfusion Injury.

    Y. Miao, L. Xie, X. Zhang, Z.-C. Ding, M. Yang, Y. Yang, P. Zhou.

  • A Proof of Concept for Liver Graft Modification Using Warm Ex Vivo Perfusion – “It Is Not Just About Rescuing Marginal Grafts”.

    N. Goldaracena, J. Echeverri, N. Selzner, D. Grant, J. Feld, M. Selzner.

  • A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.

    S. Tremblay,1 A. Shields,1,2 R. Alloway,1 P. Brailey,1 A. Leino,1 A. Lichvar,1 B. Abu Jawdeh,1 J. Driscoll,1 A. Girnita,1 E. Woodle.1

  • A Prospective Observational Study to Evaluate Use of a Panel of Reactive T Cell (PRT) Assay as a Pre-Transplant Marker of Rejection in Kidney Transplant Recipients.

    D. Brennan,1 L. Kayler,2 D. Wojciechowski,3 A. Limaye,4 A. Gaber,5 I. Durrant.6

  • A Regulatory T Cell (Treg)-Intrinsic Role for p27kip1 in Acquired Transplant Tolerance.

    P. Morawski, L. Wang, X. Yang, Y. Chen, W. Hancock, A. Wells.

  • A Retrospective Study on the Impact of Abdominal Surgical Histories on Hand-Assisted Laparoscopic Donor Nephrectomy for Living Donor Adult Kidney Transplant.

    T. Hiramitsu, K. Futamura, M. Okada, M. Tsujita, N. Goto, S. Narumi, Y. Watarai.

  • A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.

    G. de Graav,1 C. Baan,1 M. Clahsen-van Groningen,2 R. Kraaijeveld,1 M. Dieterich,1 W. Verschoor,1 D. Roelen,3 M. Cadogan,1 J. van de Wetering,1 J. van Rosmalen,4 W. Weimar,1 D. Hesselink.1

  • A Single Center Retrospective Review of Pediatric Kidney Transplant Outcomes According to Banff Grade and Cellular Rejection Treatment.

    J. Chen,1 R. Liverman,2 R. Garro,2,3 S. Jernigan,2,3 P. Winterberg.2,3

  • A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.

    N. Kapila,1 B. Zervos,2 B. Ismail,1 G. Schnickel,2 J. Rivas,2 D. Reino,2 N. Agrawal,2 A. Tzakis.2

  • A Single Skin Commensal Strain Is Sufficient to Accelerate Skin Transplant Rejection.

    Y. Lei,1 L. Chen,1 Y. Wang,1 A. Chong,1 Y. Belkaid,2 M.-L. Alegre.1

  • A Study on Gene Expression of the Protective Effect of Nitric Oxide Releasing Nanofiber in Rat Renal Ischemia-Reperfusion Injury.

    H. Ahn,1 S. Joo,1 H. Ko,1 K. Jung,1 J. Shin.2

  • A Surge in Liver Donors After Years of Decline, Is This the Tip of the Iceberg?

    A. Rana,1 M. Goss,1 J. Rees,2 M. Kueht,1 J. Vierling,1 A. Mindikoglu,1 K. Halazun,3 N. Sussman,1 B. Kaplan,4 P. Wood,5 N. Galvan,1 R. Cotton,1 C. O'Mahony,1 J. Goss.1

  • A Swine for Human MHC Class I Swap: Implications for Xenotransplantation.

    J. Ladowski,1 R. Santos,2 L. Reyes,1 G. Martens,1 J. Butler,2 R. Sidner,1 Z.-Y. Wang,1 C. Cunningham,2 M. Tector,1 A. Tector.1

  • A Thirteen-Year Mayo Clinic Retrospective Study of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013.

    M. Onuigbo,1,2 N. Agbasi.3

  • A Universal Strategy to Characterize Allograft Infiltrating Cells by Bioinformatics Deconvolution of Next Generation Sequencing Data.

    G. Thareja,1 H. Yang,2 S. Hayat,1 C. Li,2 F. Mueller,2 C. Snopkowski,2 L. Perry,2 M. Magruder,2 J. Lee,2 D. Dadhania,2 K. Suhre,1 M. Suthanthiran,2 T. Muthukumar.2

  • A UNOS Database Analysis of Patient Outcomes from Kidney Alone versus Simultaneous Kidney Liver Transplants Utilizing Matched Donor Pairs.

    T. Zens, J. Danobeitia, P. Stahler, G. Leverson, R. Redfield III, A. D'Alessandro, L. Fernandez.

  • A-Antigen (Ag)-Specific Tolerance Following A-Ag Administration to Infant Mice.

    B. Motyka,1 Y. Wang,1 B. Lamarche,1 I. Adam,1 J. Pearcey,1 K. Tao,1 C. Cairo,2 P. Cowan,3 L. West.1

  • A2 Incompatible Kidney Transplantation: A Single Center Experience.

    L. Kamal, M. Ajaimy, M. Lubetzky, G. DeBoccardo, P. Bedi, S. Greenstein, J. Rocca, J. Graham, M. Kinkhabwala, A. Chokechanachaisakul, A. Courson, E. Akalin.

  • AAV8 Delivery of TIMP-1 Prevents Hepatocyte Apoptosis After Liver Ischemia/Reperfusion Injury.

    S. Duarte, P. Matian, M. Miller, R. Busuttil, A. Coito.

  • ABO Incompatible Deceased Donor Renal Transplantation: Exploring the Possibilities.

    M. Sypek,1,2 R. Masterson,1,2 P. Hughes.1,2

  • ABO-Incompatibility Using Ritiuximab Does Not Increase Hepatocellular Carcinoma Recurrence After Liver Transplantation.

    J. Kim, S. Kim, J. Lee, K.-S. Kim, J. Lee, G.-S. Choi, J. Park, C. Kwon, J.-W. Joh, S.-K. Lee.

  • Abrogating MyD88 Signaling in Donor Lung Resident Hematopoietic Cells Promotes Cell Based Tolerance Induction in Lung Allografts in Mice.

    Z. Zheng,1 J. Wang,1 X. Yeap,1 L. Li,3 L. Zhang,2 M. He,1 X. Luo,2 Z. Zhang.1

  • Absence of Independent and Additional Predictive Ability of Preimplantation Kidney Allograft Biopsies for Long-Term Outcome: Population Based Study.

    O. Aubert, D. Viglietti, C. Loheac, M. Rabant, C. Gosset, J. Duong Van Huyen, D. Glotz, C. Legendre, C. Lefaucheur, A. Loupy.

  • Accelerated De-Novo Donor-Specific Antibody-Mediated Rejection in a Non-Human Primate Model of Renal Transplantation.

    J. Danobeitia, P. Chlebeck, J. Torrealba, T. Zens, L. Zitur, A. D'Alessandro, L. Fernandez.

  • Accelerated Rejection of Secondary Third Party Allografts in Older Recipients Is Facilitated by an Augmented Innate Immune Response.

    T. Heinbokel, K. Minami, A. Elkhal, S. Tullius.

  • Accepting a High-KDPI Kidney versus Waiting for Another Offer Can Improve Chances of a Functioning Graft.

    A. Wey,1 N. Salkowski,1 W. Kremers,2 A. Israni,1 B. Kasiske,1 J. Snyder.1

  • Access to Living Donor Kidney Transplantation in Nepal.

    P. Shrestha,1 S. Rasmussen,1 A. Thomas,1 S. Ferguson,2 A. Massie,1 D. Segev,1 P. Shrestha.3

  • Access to Simultaneous Pancreas and Kidney Transplant (SPK) Should Not Be Restricted to BMI > 28.

    M. Laftavi, A. Gruessner, V. Whittaker, Z. Acun, O. Pankowycz, R. Gruessner.

  • Accumulating Mitochondrial DNA in Aging Augments Inflammatory Responses Subsequent to IRI.

    M. Seyda,1,2 M. Quante,1 T. Heinbokel,1 G. Liu,1 H. Uehara,1 J. Schuitenmaker,1 R. Abdi,3 C. Falk,2 A. Elkhal,1 S. Tullius.1

  • Accuracy of Computed Tomography for Detecting Hepatic Steatosis in Donors for Liver Transplantation.

    Z. Guo, D. Zheng, X. He, G. Chen.

  • Achieving Ideal Outcome After Intestinal Transplantation: How Close Are We?

    A. Ganoza,1 N. Celik,1 G. Bond,1 K. Soltys,1 J. Rudolph,2 R. Sindhi,1 G. Mazariegos.1

  • Acthar in Recurrent Focal Segmental Glomerular Sclerosis After Kidney Transplantation.

    T. Alhamad,1 J. Dieck,2 V. Vujjini,2 B. Kanawati,1 D. Brennan,1 N. Alachkar.2

  • Activated Th1 and Th17 cTFH Phenotype Correlates with DSA Production in Kidney Transplant Recipients.

    C. Macedo, P. Fadakar, K. Hadi, B. Ellinof, A. Zeevi, S. Hariharan, D. Metes.

  • Activation of Inflammation Amplifier in Kidney Graft and Urinary Biomarker for Chronic Rejection.

    H. Higuchi,1,2 D. Iwami,1 K. Hotta,1 N. Shinohara,1 M. Murakami.2

  • Acute Antibody-Mediated Rejection in Pediatric Liver Transplantation.

    C. Eriksen,1 M. Zimmerman,1 J. Kim,1 S. Lerret,2 G. Telega,2 B. Vitola,2 J. Schiller,3 J. Hong.1

  • Acute Cellar Rejection and Long-Term Graft Survival in Pediatric Kidney Transplant Recipients.

    A. Massie, J. Garonzik-Wang, N. Desai, D. Segev.

  • Acute Cellular Rejection Is Associated with Increased Risk of Early and Late Graft Failure.

    A. Massie, J. Garonzik-Wang, D. Segev.

  • Acute Mouse CMV Infection Abrogates Transplant Tolerance by Modulating Myeloid Cell Differentiation and Function: A Possible Role for Transcription Factor RORγt.

    A. Dangi,1 L. Zhang,1 X. Zhang,2,3 Z. Zhang,2,3 X. Luo.1,2,3

  • Acute Rejection in 6 Antigen HLA Matched Kidney Transplant Recipients: Risk Factors and Outcomes.

    A. Condon, B. Astor, K. Holdener, T. Ellis, A. Djamali.

  • Acute Renal Replacement Therapy in Pediatric Liver Transplantation: A Predictor of Increased Risk.

    M. Wong,1 R. Venick,2 V. Agopian,1 S. Ebaid,1 S. McDiarmid,2 A. Zarrinpar,1 D. Farmer,1 R. Busuttil,1 F. Kaldas.1

  • Addition of FEV1 Drop to LAS May Improve Access of CF Patients to Transplant: Analysis of the SRTR and US CF Foundation Patient Registries.

    E. Dasenbrook,1 M. Skeans,2 A. Fink,3 B. Marshall,3 M. Valapour.1,2

  • Addition of hEPCR.hCD55.hTFPI.hCD47 Modulates Multi-Lineage Cell Sequestration and Coagulation Activation by GalTKO.hCD46 Transgenic Pig Livers Perfused Ex Vivo with Human Blood.

    A. Cimeno,1 L. Burdorf,1 D. Parsell,1 C. Phelps,2 D. Ayares,2 A. Azimzadeh,1 R. Pierson III,1 R. Barth,1 J. LaMattina.1

  • Adjunctive Thymoglobulin with Proteasome Inhibitor Based Treatment of Late Mixed Acute Rejection.

    A. Lichvar,1 A. Leino,1 S. Tremblay,1 A. Shields,2 F. Paterno,1 A. Govil,1 M. Anand,1 T. Diwan,1 J. Kremer,2 R. Alloway,1 E. Woodle.1

  • Adjuvant Chemotherapy with Gemcitabine Plus Cisplatin for Kidney Transplant Patients with Transitional Cell Carcinoma.

    Z. Wang, J. Lin, Y. Zhu, J. Zhang, J. Xiao, Y. Guo, Y. Tian.

  • Adoptive Immunotherapy with Liver Allograft-Derived Lymphocytes Compensate for the Susceptibility to Post-Liver Transplant Blood Stream Infection Associated with FCGR3A SNP.

    H. Ohdan, M. Ohira, S. Shimizu, Y. Tanaka, H. Tahara, K. Ide, K. Ishiyama, T. Kobayashi.

  • Advanced Donation within a Paired Exchange Program.

    M. Charlton,1 F. Desrosiers,1 G. Bretzlaff,1 D. Serur.2

  • African American Living Kidney Donors' Attitudes About APOL1 Genetic Testing: Implications for Evaluation and Informed Consent.

    E. Gordon,1 C. Johnson,1 C. Wicklund,1 R. Sharp,2 J. Friedewald.1

  • Age and Gender Disparities in Post-Lung Transplant Mortality.

    H. Maredia, M. Bowring, A. Massie, S. Oyetunji, C. Merlo, R. Higgins, D. Segev, E. Bush.

  • Age and Race Disparities Among Pediatric and Adult Cystic Fibrosis Lung Transplant Recipients.

    H. Maredia, M. Bowring, A. Massie, S. Oyetunji, C. Merlo, R. Higgins, D. Segev, E. Bush.

  • Age-Related Differences in Gene Expression Among Kidney Allografts with Normal Histology and Calcineurin Inhibitor Nephrotoxicity.

    E. Rhone,1 S. Bontha,1 P. Walker,2 C. Dumur,3 D. Maluf,1 J. Almenara,3 V. Mas.1

  • Albuminuria in Kidney Transplant Patients Is Associated with Increased Urine Serine Proteases with the Ability to Activate ENaC.

    G. Hinrichs,1 C. Bistrup,2 H. Birn,3 B. Jensen.1

  • Alcohol-Induced Hepatic Cirrhosis Is Rising Among Young Adults.

    C. Kling,1 J. Perkins,1 D. Donovan,2 R. Carithers,3 L. Sibulesky.1

  • Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts.

    T. Sparkes, B. Ravichandran, O. Opara, R. Ugarte, J. Bromberg, R. Barth.

  • Alemtuzumab Induction Is Associated with a Lower Incidence of BK Virus Nephropathy Compared with IL2RA Induction.

    A. Gueret-Wardle, S. Hassan, G. Lucisano, C. Roufosse, M. Willicombe, D. Taube.

  • Alemtuzumab Induction Is Safe, and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients.

    A. Seitz,1 M. Robb,2 N. Ahmad,1 A. McLean,3 D. Taube,3 R. Johnson,2 R. Baker.1

  • Alemtuzumab Use in a Single Center Pediatric Heart Transplant Cohort.

    J. Case,1 J. Eshelman,2 P. Booker,2 S. Miyamoto,3 M. Everitt,3 S. Auerbach.3

  • Allograft Crescent Predicts Graft Failure in Recurrent IgA Nephropathy Patients.

    S. Park, H. Cho, M.-Y. Yu, Y. Kim, K. Moon, Y. Kim, H. Lee.

  • Allograft Cytokine Activation and Elevated Tissue Indoleamine 2,3-Dioxygenase Gene and Protein Expression in Rejecting Pig Transplants.

    T. Merchen,1 Y. Wang,2 R. Lassiter,1 D. Kleven,3 R. Jajosky,3 M. Winn,2 C.-S. Ho,5 N. Nahman.4

  • Alloimmune Quiescence in Recipients with Long-Term Surviving Kidney Grafts.

    K. Brown,1 W. Baldwin,1 E. Poggio,2 W. Braun,2 R. Fairchild.1

  • Alternations in Amplitude of Low Frequency Fluctuation in Renal Allograft Recipients That Received Tacrolimus or Sirolimus: An fMRI Study.

    J. Wen,1 X. Ni,1 L. Wu,2 G. Zheng,2 L. Zhang,2 J. Chen.1

  • Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission.

    M. Nowicki,1,2 H. Prince,2 C. Chinchilla,2 C. De Los Santos,2 J. Trageser,3 L. Stocks.3

  • Ambulatory Antibiotic Utilization and Outcomes in an Adult Kidney Transplant Population: A Pharmacovigilance Analysis.

    L. Avery, C. Fominaya, R. Crawford, D. Taber.

  • Ambulatory Blood Pressure Monitoring Detects High Prevalence of Hypertension in Recipients of Non-Renal Transplants.

    A. Melk,1 N. Memaran Dadgar,1 B. Borchert-Mörlins,1 R. Sugianto,1 R. Blöte,1 I. Goldschmidt,1 R. Beier,2 C. Müller,3 B. Schmidt.4

  • An Analysis of Tacrolimus XL Dosing in Obese Kidney Transplant Recipients.

    N. Jasiak, J. Thielke, K. Progar, J. Chen, C. Adams, E. Benedetti, P. West-Thielke.

  • An Argument for Expanding the Simultaneous Liver and Kidney Transplant Criteria: Validity of the New UNOS Allocation Policy.

    S. Nagai,1 M. Safwan,1 K. Collins,1 M. Rizzari,1 D. Moonka,2 K. Brown,2 A. Patel,3 A. Yoshida,1 M. Abouljuod.1

  • An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.

    R. Sigireddi, J. Moffett, M. Kueht, R. Ackah, A. Rana, C. O'Mahony, J. Goss, S. Dhingra, S. Khaderi.

  • An OPO Offer Acceptance Report for Hard-to-Place Kidneys.

    A. Wey, N. Salkowski, B. Kasiske, A. Israni, J. Snyder.

  • Analysis of ApoL1 and MYH9 Genetic Polymorphisms Among the Hispanic Kidney Allograft Recipients.

    Y. Chang,1,2 T. Shah,1,3 D. Min.1

  • Analysis of Differences in Living Donor and Recipient Pairs Estimated GFR at Six Months Over Time.

    D. Keith.

  • Analysis of Outcomes in High Risk Kidney Transplants.

    E. Liu, M. Aull, J. Lee, S. Kapur.

  • Anastomosis Time During Liver Transplantation Impairs Transplant Survival.

    I. Jochmans,1 S. Fieuws,2 I. Tieken,3 U. Samuel,3 J. Pirenne.1

  • Angioplasty versus Stent in the Treatment of Transplant Renal Artery Stenosis.

    L.-X. Chen,1 G. Fananapazir,2 H. Bang,3 M. Gandhi,1 M. Alnimri,1 B. Gallay,1 A. De Mattos.1

  • Anti-Angiotensin Type 1 Receptor Antibodies Associate with Rejection in Simultaneous Pancreas and Kidney Transplant and Pancreas Transplant Alone Recipients.

    A. Peng, D. Dafoe, J. Choi, A. Vo, X. Zhang, R. Najjar, E. Huang, S. Jordan.

  • Anti-CD25mAb Sparing Immunosuppressive Regimen Suppressed Recurrence of Post-Transplant Focal Segmental Glomerular Sclerosis- A Single Center Experience.

    H. Harada, Y. Wada, N. Fukuzawa.

  • Anti-CD40 mAb Promotes Kidney Immunoregulatory Capacity in NHP Transplants by Altering Kidney Tubular Cell (TEC) Expression of CD40 and IL-6.

    J. Arp,1 Y. Ma,1 H. Yang,2 A. El Warrak,1 A. Haig,1 W. Liu,1 K. Reimann,3 P. Luke,1 Z. Zhang,1 D. Rothstein,4 A. Jevnikar.1

  • Anti-HLA I Antibody Enhances Endothelial Cell-Induced Polarization of Human Monocytes to M2a/c-Like Macrophages.

    X. Wei, N. Valenzuela, M. Rossetti, E. Reed.

  • Antibiotic Conservatorship in Orthotopic Liver Transplantation.

    J. Yee,2 D. Clark,2 R. Hogen,1,2 K. Dhanireddy,1 S. Biswas,2 J. Cobb,2 K. Matsushima,2 D. Grabo,2 A. Strumwasser.2

  • Antibiotic Prophylaxis Against Urinary Tract Infections After Renal Transplant.

    P. Klem,1 J. Gralla,2 D. Chang,1 A. Wiseman,2 S. Davis,2 J. Cooper.2

  • Antibodies Specific for HLA Class I and Lung Associated Self-Antigens, Kα1Tubulin and Collagen V, Induces Exosomes Following In Vitro Binding to Human Airway Epithelial Cells.

    M. Gunasekaran, M. Sharma, S. Bansal, S. Biswas Roy, R. Walia, M. Smith, R. Bremner, T. Mohanakumar.

  • Antibodies to Angiotensin Type II Receptor I Are Associated with Primary Graft Dysfunction After Orthotopic Heart Transplant in Patients with Ventricular Assist Device as Bridge to Transplant.

    M. Hickey,1 E. DePasquale,2 S. Shah,3 D. Vucicevic,2 J. Zhang,1 N. Valenzuela,1 M. Deng,2 E. Reed.1

  • Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction.

    D. Nayak,1 K. Garcia,2 P. Pirrotte,2 R. Hachem,3 R. Bremner,1 M. Smith,1 T. Mohanakumar.1

  • Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.

    P. McMullen II,1 J. Xin,1 N. Brown,1 R. Upchurch,1 J. Weidner,1 S. Fedson,2 A. Husain,1 S. Marino.1

  • Antibody-Mediated Vascular Rejection of Kidney Allografts: What Does It Happen After 15 Years?

    B. Rodriguez Cubillo,1 I. Perez Flores,1 M. Moreno De La Higuera,1 M. Calvo,1 N. Calvo Romero,1 A. Pascual,2 J. Cortes,2 J. Blanco,2 A. Sanchez-Fructuoso.1

  • Antidepressant Medication Use Before and After Kidney Transplant: Implications for Post-Transplant Outcomes.

    K. Lentine,1 A. Naik,2 R. Ouseph,1 Z. Zhang,1 D. Axelrod,3 D. Segev,4 V. Dharnidharka,5 D. Brennan,5 H. Randall,1 R. Gadi,1 N. Lam,6 G. Hess,7 M. Schnitzler,1,8 B. Kasiske.8

  • Antioxidant Thermoresponsive Hydrogel as a Versatile Islets Scaffolds for Treating Type I Diabetes.

    Y. Zhu,1 X. Zhang,2 G. Ameer,1 X. Luo.2

  • Antiretroviral Therapy Modification of HIV+ Patients Listed for Kidney Transplantation.

    D. Lee,1 G. Malat,3 T. Bias,1 S. Epstein,1 L. Levin Mizrahi,2 M. Harhay,2 S. Talluri,2 K. Ranganna.2

  • APOL1 Genotype Does Not Affect Donor Renal Function Post Live Kidney Donation.

    K. Koutroutsos,1 R. Sergeant,2 F. Powell,2 C. Freeman,2 R. Charif,1 J. Galliford,1 P. Brookes,2 D. Taube,1 M. Loucaidou.1

  • Apoptotic Exosome-Like Vesicles Released During Tissue Injury Trigger IL23/IL-17 Autoimmune Axis and Accelerate Rejection.

    M. Dieudé,1,4 J. Turgeon,1,4 A. Karakeussian-Rimbault,1,4 L. Pomerleau,1 A. Robitaille,1 N. Grandvaux,1 É. Boilard,2,4 M.-J. Hébert.1,3,4

  • Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial.

    G. Whitehouse, N. Safinia, S. Thirkell, L. Fry, N. Grageda, M. Martinez-Llordella, R. Lechler, N. Heaton, G. Lombardi, A. Sanchez-Fueyo.

  • APRIL/BLyS Inhibition Reduces Donor Specific Antibody in Sensitized Mice.

    B. Bolt, N. Wilson Schlei, B. Verhoven, R. Redfield.

  • Aquaporin 4 Blockade Alters T Cell Anatomical Distribution and Prolongs Cardiac Allograft Survival in Sensitized Recipients.

    M. Nicosia,1 R. Fan,1 G. Farr,2 M. Pelletier,2 P. McGuirk,2 K. Ayasoufi,1 A. Valujskikh.1

  • Are Drains Required After Donor Hepatectomy?

    S. Sharma, S. Kumar, K. Yadav, S. Sable, A. Chauhan, S. Kapoor, V. Varma, V. Kumaran.

  • Are ICD-9 V Codes Representative of the Liver Transplant Wait List?

    Y. Bababekov, D. Chang, Y.-C. Hung, J. Adler, S. Stapleton, J. Markmann, H. Yeh.

  • Aryl Hydrocarbon Receptor Regulates Myeloid Derived Suppressor Cells by Activating the ERK Signaling in a Murine Cardiac Transplantation Model.

    T. Nakamura, K. Masuda, N. Yoshimura.

  • ASP0113 Elicits an Immune Response in CMV-Seronegative Dialysis Patients: Comparison to Healthy Subjects.

    P. Bonate,1 C. Van Sant,2 K. Cho,1 E. Zook,1 L. Smith,3 S. Boutsaboualoy, X. Wang,1 R. Wu,1 A. Koester,4 D. Rammelsberg,6 R. Goldwater,4 T. Marbury.5

  • Assessing Self-Efficacy During the Transition from Pediatric to Adult Liver Transplant Care.

    J. Bilhartz, M. Lopez, S. Eder, E. Fredericks.

  • Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.

    A. Vo,1 S. Williamson,1 K. Myers,1 E. Huang,1 J. Choi,1 X. Zhang,2 A. Peng,1 R. Najjar,1 S. Jordan.1

  • Assessment and Transplantation of Declined Human Kidneys Using Ex-Vivo Normothermic Kidney Perfusion.

    S. Hosgood,1 M. Hamed,1 A. Sawpaul,2 R. Figueiredo,2 K. Saeb-Parsy,1 C. Wilson,2 M. Nicholson.1

  • Assessment of a Medication Education Program Among New Transplant Recipients at a Large Academic Health Center.

    G. Meadows,1 J. Kyle,1 A. Dodson,1 K. Gutierrez,1 P. MacLennan,2 F. Iqbal,2 L. Weldon,1 D. Jones,1 A. James.1

  • Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.

    S. Kilaru,1 E. Tapper,2 M. Curry.3

  • Assessment of C4d Positive Biopsies with No Histological Evidence of Inflammation Using Nanostring nCounter Technology.

    K. Dominy,1 M. Willicombe,3 T. Al Johani,2 J. Galliford,3 A. McLean,3 T. Cook,3 C. Roufosse.3

  • Assessment of Cardiosphere-Derived Cell Exosomes as Possible Modulator of Alloimmunity in a Mouse Model of HLA-A2 Allosensitization.

    I. Kim,1 G. Wu,1 N.-N. Chai,1 G. De Couto,2 E. Marban,2 A. Klein,1 S. Jordan.1

  • Assessment of Donor-Reactive T-Cell Immunity by the Novel Urine Cell-Derived Alloantigen Assay Allows Prediction of Acute Rejection in Renal Transplant Patients.

    C. Thieme,1 B. Weist,1 A. Müskes,1 P. Reinke,1 T. Westhoff,2 N. Babel.1,2

  • Assessment of Islet Damage During Isolation Utilizing miRNAs and Its Significance with Post-Transplant Outcome in TPIAT.

    P. Saravanan,1 M. Kanak,2 G. Yoshimatsu,1 M. Lawrence,1 B. Naziruddin.3

  • Assessment of Simple Indices Based on a Single Fasting Blood Sample in Search for an Optimal Tool to Estimate Beta Cell Function After Islet Transplantation.

    J. Golebiewska,1 J. Solomina,2 E. Konsur,2 K. Cieply,2 L. Basto,2 A. Kotukhov,2 K. Golab,2 C. Thomas,3 A. Debska-Slizien,1 P. Witkowski.2

  • Assessment of the Association Between Measures of Metabolic Function and Pancreas Graft Survival.

    S. Mittal,1 R. Franklin,2 J. Levy,2 S. Gough,2 E. Sharples,1 P. Friend.1

  • Assessment of the Risk Index for Living Donor Kidney Transplantation (LKDPI) in a European Cohort.

    O. Staeck, G. Rehse, D. Khadzhynov, A. Kleinsteuber, L. Lehner, M. Duerr, K. Budde, F. Halleck.

  • Assessments of Literacy, Cognitive Function and Transplant Medication Knowledge in Renal Transplant Recipients.

    J. Trofe-Clark,1 W. Gbemudu,2 S. Ryan,2 D. Sawinski,1 M. Lim,1 S. Goral,1 M. Bleicher,1 R. Bloom,1 P. Reese.1

  • Association Between Matrix-gla Protein Levels and Aortic Stiffness in Kidney Transplantation.

    M. Dinic,1 N. Maillard,1 P. Delanaye,2 J.-M. Krzesinski,2 A.-M. Saint-Remy,2 E. Cavalier,3 C. Mariat.1

  • Association Between Transportation Strategies and Kidney Transplant Center Staff Perceived Racial Disparities.

    K. Lipford, L. McPherson, R. Hamoda, R. Patzer.

  • Association of BK and CMV Viremia with Pancreas Allograft Survival Among Adults Receiving Simultaneous Pancreas and Kidney Transplant: The Wisconsin Allograft Recipient Database (WisARD).

    F. Aziz, B. Astor, S. Parajuli, N. Garg, B. Muth, D. Mandelbrot, A. Djamali, D. Kaufman, J. Odorico, H. Sollinger, M. Mohamed.

  • Association of Dialysis Facility Neighborhood Socioeconomic Status with Barriers to Kidney Transplant.

    K. Ross,1 M. Basu,2 C. Escoffery,3 J. Gander,2 S. Mohan,4 S. Pastan,2 L. Plantinga,1 K. Smith,2 R. Patzer.1,2

  • Association of Non-HLA Antibodies with Histological Changes of Antibody Mediated Injury in Kidney Transplantation.

    N. Leca,1 I. Gimferrer,2 P. Warner,2 K. Nelson,2 R. Bakthavatsalam,1 L. Sibulesy,1 B. Najafian,3 C. Robinson-Cohen,1 B. Kestenbaum.1

  • Association with Tacrolimus Intraindividual Variability, Acute Microinflammation Based on 1 Year-Transplanted Kidney Biopsy After Transplantation, and Biopsy-Proven Acute Rejection.

    S.-Y. Kim, S.-I. Min, W. Cho, S. Cho, M.-J. Cho, S. Ahn, S.-K. Min, J. Ha.

  • Associations Between Provision of Transplant Pharmacy Services and Center-Level Patient and Graft Outcomes in U.S. Adult Kidney Transplant Programs.

    J. Park,1 J. Trofe-Clark,2 T. Kaiser,3 N. Pilch,4 D. Taber.4

  • At-Home Transplant Education Increases Black and Low-Income Dialysis Patients' Transplant Knowledge, Attitudes, Informed Decision-Making, and Pursuit: An Explore Transplant @ Home Randomized Controlled Trial.

    A. Waterman,1 J. Peipert,1 A.-M. McSorley,1 C. Goalby,1 L. Peace.2

  • Autologous Expanded Tregs and Porcine Hematopoietic Cells to Prolong Xenogeneic Pig Skin Graft Acceptance in Baboons.

    J. Stern,1 S. Kofman,1 P. Alonso-Guallart,1 E. Berglund,1 M. Danton,1 J. Weiner,1 D. Ayares,2 R. Hawley,1 K. Yamada,1 D. Sachs,1 M. Sykes,1 A. Griesemer.1

  • Autophagy Regulates LG3 Maturation and Export in Apoptotic Exosome-Like Vesicles.

    D. Beillevaire,1,2,4 M. Francis,1,2,4 G. Diane,2 B. Éric,3,4 D. Mélanie,1,2,4 H. Marie-Josée.1,2,4

  • Autotransplantation of the Left Lung for the Treatment of Recurrent Life Threatening Pulmonary Hemorrhage Related to Pulmonary Vascular Malformation: A Unique Chance to Study Ischemia/Reperfusion Injury.

    C. Falk,1 I. Tudorache,2 C. Müller,3 W. Sommer,2 K. Daemen,1 J. Keil,1 G. Hansen,3 A. Haverich,2 G. Warnecke,2 N. Schwerk.3

  • Avascular Necrosis in Kidney Transplant Recipients: Recent Data from a Cohort Study.

    P. Perrin,1 R. Felten,2 S. Caillard,1 M. Schaeffer,3 B. Moulin,1 R.-M. Javier.2

  • Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.

    M. Okada,1 Y. Watarai,1 K. Iwasaki,2 K. Murotani,3 T. Hiramitsu,1 M. Tsujita,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

  • Awareness of Change in the Kidney Allocation System Among Dialysis Providers from Facilities with Low Waitlisting.

    M. Basu,1 K. Smith,1 S. Pastan,1 L. Plantinga,1,2 S. Mohan,3 C. Escoffery,2 J. Chung,1 T. Melanson,2 R. Patzer.1,2

Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2023 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences